William Blair analyst Matt Phipps reiterated a Buy rating on Janux Therapeutics Inc today and set a price target of $14.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors, including the view that Janux’s current share price, which is trading below its cash balance, does not fairly reflect the value of its pipeline. He sees JANX007 as a potentially best-in-class therapy for metastatic castration-resistant prostate cancer based on data released to date, particularly at the doses now progressing into Phase Ib.
He also highlights the planned clinical update for JANX007 at a major medical conference in the first half of 2027 as a key catalyst that could restore investor confidence and re-rate the stock. In addition, he points to upcoming initial data for JANX011 later this year and growing industry interest in autoimmune T-cell engagers as supportive of further upside, and therefore maintains his Outperform rating with an unchanged $14 price target.
According to TipRanks, Phipps is a 4-star analyst with an average return of 5.3% and a 44.72% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Compass Therapeutics, and Evommune, Inc..